<?xml version='1.0' encoding='utf-8'?>
<document id="26372268"><sentence text="Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety." /><sentence text="Use of 'party drugs', a particular set of recreational drugs used in the context of 'ChemSex', is frequent among MSM living with HIV" /><sentence text=" A recently published observational study showed that more than half of HIV-infected MSM interviewed reported use of illicit substances in the previous 3 months, with frequent concomitant use of three or more drugs" /><sentence text=" These substances are a combination of 'club drugs' (methylenedioxymethamphetamine, gamma-hydroxybutyrate, ketamine, benzodiazepine) and drugs that are more specifically used in a sexualized context (methamphetamine, mephedrone, poppers and erectile dysfunction agents)"><entity charOffset="53-82" id="DDI-PubMed.26372268.s4.e0" text="methylenedioxymethamphetamine" /><entity charOffset="84-105" id="DDI-PubMed.26372268.s4.e1" text="gamma-hydroxybutyrate" /><entity charOffset="107-115" id="DDI-PubMed.26372268.s4.e2" text="ketamine" /><entity charOffset="117-131" id="DDI-PubMed.26372268.s4.e3" text="benzodiazepine" /><entity charOffset="200-215" id="DDI-PubMed.26372268.s4.e4" text="methamphetamine" /><entity charOffset="217-227" id="DDI-PubMed.26372268.s4.e5" text="mephedrone" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e0" e2="DDI-PubMed.26372268.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e1" e2="DDI-PubMed.26372268.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e1" e2="DDI-PubMed.26372268.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e1" e2="DDI-PubMed.26372268.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e1" e2="DDI-PubMed.26372268.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e1" e2="DDI-PubMed.26372268.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e2" e2="DDI-PubMed.26372268.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e2" e2="DDI-PubMed.26372268.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e2" e2="DDI-PubMed.26372268.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e2" e2="DDI-PubMed.26372268.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e3" e2="DDI-PubMed.26372268.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e3" e2="DDI-PubMed.26372268.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e3" e2="DDI-PubMed.26372268.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e4" e2="DDI-PubMed.26372268.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26372268.s4.e4" e2="DDI-PubMed.26372268.s4.e5" /></sentence><sentence text=" Although formal data on pharmacokinetic or pharmacodynamic interactions between recreational drugs and antiretroviral agents are lacking, information regarding potentially toxic interactions can be theorized or sometimes conclusions may be drawn from case studies and cohort observational studies" /><sentence text=" However, the risk of coadministering party drugs and antiretrovirals should not be overestimated" /><sentence text=" The major risk for a drug-drug interaction is when using ritonavir-boosting or cobicistat-boosting agents, and maybe some nonnucleoside reverse transcriptase inhibitors"><entity charOffset="58-67" id="DDI-PubMed.26372268.s7.e0" text="ritonavir" /></sentence><sentence text=" Knowledge of the metabolic pathways of 'party drugs' may help in advising patients on which illicit substances have a high potential for drug-drug interactions, as this is not the case for all" /><sentence text=" " /></document>